J. Cruz

GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS)

J. Mora, E. de Álava, J. Martín-Broto, 2017, British Journal of Cancer.

Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients

J. Martín-Broto, C. Serrano, J. López-Guerrero, 2018, Oncotarget.

Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX®/Doxil®) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS)

C. Balañà, A. Poveda, R. Bernabé, 2005, Sarcoma.

A phase II study of a new formulation of nonpegylated liposomal doxorubicin (doxorubicin GP-pharm) as first-line treatment in patients with advanced soft-tissue sarcomas (STS) who are age 65 or older: A GEIS trial.

C. Balañà, R. Andrés, C. Valverde, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Trial of Doxorubicin Plus Escalated High-Dose Ifosfamide in Patients With Advanced Soft Tissue Sarcomas of the Adult: A Study of the Spanish Group for Research on Sarcomas (GEIS)

A. Casado, P. Escudero, A. López-pousa, 2006, Sarcoma.

SEOM clinical guidelines for the treatment of head and neck cancer (2020)

J. Lambea, R. Mesía, L. Iglesias, 2021, Clinical and Translational Oncology.

REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial

J. Blay, A. Italiano, J. Martín-Broto, 2023, Molecular Cancer.